Conflict of interest: Nothing to declare.
Conventional and molecular cytogenetic characterization of Burkitt lymphoma with bone marrow involvement in Brazilian children and adolescents
Article first published online: 26 MAR 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 8, pages 1422–1426, August 2014
How to Cite
De Souza, M. T., Hassan, R., Liehr, T., Marques-Salles, T. J., Boulhosa, A. M., Abdelhay, E., Ribeiro, R. C. and Silva, M. L. M. (2014), Conventional and molecular cytogenetic characterization of Burkitt lymphoma with bone marrow involvement in Brazilian children and adolescents. Pediatr. Blood Cancer, 61: 1422–1426. doi: 10.1002/pbc.25030
- Issue published online: 10 JUN 2014
- Article first published online: 26 MAR 2014
- Manuscript Accepted: 19 FEB 2014
- Manuscript Received: 24 SEP 2013
- CAPES (PROBRAL/DAAD—project no. 419/14)
- CNPq (project no. 473878/2011-9)
- FAPERJ (project no. E-26/110.868/2013)
- INCT para Controle do Câncer, Brazil. Grant Number: CNPq 573806/2008-0
- American Lebanese Syrian Associated Charities (ALSAC)
- Center of Excellence Grant from the State of Tennessee
- Burkitt lymphoma/leukemia;
- IGH/MYC gene fusion;
- secondary chromosomal abnormalities;
- t(8 ;14)(q24 ;q32)
Burkitt lymphoma/leukemia (BL/L) is cytogenetically characterized by the t(8;14)(q24;q32) or its variants, t(2;8)(p11;q21), and t(8;22)(q24;q11.2), which juxtapose the MYC oncogene to one of the three immunoglobulin loci. The overall cure rate of BL/L in children is 70–90%, but patients diagnosed with advanced-stage disease have a less favorable prognosis. It is possible that secondary chromosomal abnormalities contribute to this unfavorable prognosis via chemotherapy resistance, but the results of genetic studies have been inconsistent. This study aimed to identify and characterize secondary chromosomal abnormalities associated with the t(8;14) and its variants in children with French-American-British-L3 leukemia or Burkitt lymphoma with bone marrow involvement at the time of diagnosis.
Chromosome analysis was based on G-banding. Fluorescence in situ hybridization technique was applied using IGH/MYC/CEP8 dual-fusion and MYC break-apart probes. Multicolor chromosome banding was performed according to standard protocol.
We describe a group of BL/L with extreme adverse clinical outcome, in which secondary chromosomal abnormalities, particularly those involving the long arms of chromosomes 1 and 13, were found in 71% of cases. The IGH/MYC fusion showed molecular heterogeneity in 14% of cases and two cases exhibited three IGH/MYC fusion signals.
Secondary chromosomal abnormalities were found in a high proportion of patients. We observed an extent of IGH/MYC heterogeneity not previously reported in Burkitt lymphoma, including the novel finding of three fusion signals in two cases. Pediatr Blood Cancer 2014; 61:1422–1426. © 2014 Wiley Periodicals, Inc.